PRLR and breast carcinoma: The analysis of the enriched biological processes of differentially expressed genes in PRLR-low tumors from radiotherapy-treated patients without a breast cancer event within 5 years (BCFI > 5 years, n = 262) showed the significant enrichment (Padj < 0.05) of pathways indicative of increased immune activity.